This site is intended for UK healthcare professionals only

NEWS

 

Keep up to date with the latest news on bladder health, management and treatment.

Have you got a story to share? Email the team today.

nGene Announces Positive Preliminary Phase 1/2 Data with EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
9 February 2022
Cancer
LEGEND study results released exploring Non-Muscle Invasive Bladder Cancer (NMIBC)

enGene Announces Positive Preliminary Phase 1/2 Data with EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer.

enGene Inc., a USA and Canada based clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, has announced positive results from its LEGEND study, a first-in-human Phase 1/2 clinical trial of EG-70 for the treatment of high-grade Non-Muscle Invasive Bladder Cancer (NMIBC) in patients with carcinoma in situ (CIS) that are BCG-unresponsive.

For over 30 years, the standard treatment for NMIBC has been BCG immunotherapy. However, the 60% disease recurrence and progression rates associated with BCG treatment have created an urgent unmet medical need for NMIBC patients who are left with very few options. Ultimately, the majority of NMIBC patients that do not respond to BCG will undergo radical cystectomy, a procedure in which the bladder is removed concurrently with other surrounding organs.

The results from LEGEND study to-date have shown that enGene’s novel intravesical monotherapy, EG-70, is safe and well tolerated, with encouraging clinical efficacy in high-grade NMIBC patients with CIS in whom BCG has failed. Of the six patients that have reached the 3-month efficacy assessment, five have achieved complete response (CR). This marks an 83% CR rate that is trending best-in-class for an intravesical monotherapy at the end of the first treatment cycle.

“The responses observed with EG-70 are an important step towards NMIBC patients avoiding radical cystectomy,” said Dr. Gary Steinberg, Professor and Director at the Perlmutter Cancer Center and Department of Urology Goldstein Urology Bladder Cancer Program of NYU Langone Health, and lead Principal Investigator for the LEGEND study. “If similar results are observed as the study progresses, I am confident that this novel intravesical monotherapy will make a meaningful impact in the lives of patients with high risk NMIBC.”

“We are thrilled to announce the safety and clinical efficacy of EG-70 in patients with BCG-unresponsive NMIBC who are facing bladder removal as an alternative,” said Jason Hanson, Chief Executive Officer at enGene. “EG-70 was designed ab initio as an intravesical monotherapy that would slot directly into current medical practice to provide ease-of-use and increased access to patients.”

Summary of Clinical Results

  • The analysis reported that 83% of patients evaluable for efficacy have achieved CR (N=6) at 3-months
  • There have been no DLTs or SAEs reported to date
  • AEs were limited to transient Grade 1 and Grade 2 Aes such as intermittent pain when urinating, urinary tract pain, bilateral serous otitis, increased nocturia, restlessness, and low back pain

The open label trial has a primary endpoint of safety and tolerability and a key secondary endpoint of CR rate at 3-months. With these initial data, the LEGEND study is slated to successfully meet both primary and secondary endpoints.

Find our more about the LEGEND study

Read more news from The Bladder Interest Group now.

Latest News

Luja™ shows significant improvement in bladder emptying

Study results show that Coloplast’s new intermittent male catheter with 80+ micro-holes, Luja, achieved complete bladder emptying in one free flow* in 90% of catheterisations. Coloplast has finalised its first pivotal clinical study on Luja, a new intermittent male...

Artificial Intelligence used in bladder cancer treatment assessment

A computerised artificial intelligence (AI)-based decision support system (CDSS-T) enhanced the performance of clinicians when assessing patients’ response to chemotherapy prior to radical cystectomy, according to results from a small multi-institutional observer...

New treatment for urothelial cancer approved by NICE

Over 800 people with locally advanced or metastatic urothelial cancer are set to benefit from a new treatment for urothelial cancer – avelumab – following its recommendation for routine NHS funding in final draft guidance published NICE. The recommendation for this...